BRIEF-Imdelltra® Demonstrated Superior Overall Survival In Small Cell Lung Cancer

Reuters
11 Apr
BRIEF-Imdelltra® Demonstrated Superior Overall Survival In Small Cell Lung Cancer

April 11 (Reuters) - Amgen Inc AMGN.O:

  • IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER

  • AMGEN INC - SAFETY PROFILE FOR IMDELLTRA WAS CONSISTENT WITH ITS KNOWN PROFILE.

  • AMGEN INC: GLOBAL PHASE 3 DELLPHI-304 CLINICAL TRIAL MET ITS PRIMARY ENDPOINT AT A PLANNED INTERIM ANALYSIS

  • AMGEN: IMDELLTRA SHOWED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OS VERSUS LOCAL STANDARD-OF-CARE CHEMOTHERAPY

Source text: ID:nPn3X1N6la

Further company coverage: AMGN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10